Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Peter Clark, MA, MD, FRCP: A Payer Perspective

Lymphoma

The ASCO Post Staff

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Apr

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Peter Clark, MA, MD, FRCP: A Payer Perspective

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Combined Tests Could Avoid Unnecessary Cystectomy, Study Finds

American Cancer Society Announces New Pediatric Adolescent and Young Adult Cancer Journal

Colorectal Cancer Duloxetine Not Effective in Preventing Oxaliplatin-Induced Peripheral Neuropathy

Advanced Prostate Cancer Radiographic Progression and PSA Increase in Patients Treated With Enzalutamide

CLL Linked to Increased Skin Cancer Risk and Mortality